Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 years of age
Histologically proven diagnosis of NSCLC at MSKCC Tumor positive for a translocation or inversion event involving the ALK gene locus
Clinical response to treatment with crizotinib as defined by either:
Radiographic partial or complete response defined by RECIST or WHO
OR:
Radiographic stable disease for at least 8 weeks
Radiographic progression of disease amenable to biopsy while on treatment with crizotinib as defined by RECIST or WHO
Signed informed consent
You may not be if
Deemed by their treating physician to be medically unfit for biopsy
Women who are pregnant or breast-feeding
Clareo Health | Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
